MONTRÉAL, June 15, 2022 – Imagia Canexia Health, a genomics-based cancer treatment testing company that accelerates access to precision care by combining AI expertise with advanced molecular biopsy solutions, today announced the CE-IVD marking for its Imagia Canexia Health Insights Platform (ICHIP) to operate across Europe.
June 3, 2022
This article from BioWorld Medtech includes an interview with our CMO David Huntsman, where he discusses Imagia Canexia Health's Candetect project, which is developing precision oncology software that will help monitor resistance to cancer therapy and treatment relapse in individual cancer survivors.
May 19, 2022
Health is becoming digital health, encompassing everything from electronic patient records to telemedicine and mobile health — spurred on by the pandemic. But the next evolution will involve artificial intelligence. While the potential of AI is enormous, there are still a number of challenges to delivering impactful solutions for clinical adoption.
April 21, 2022
Vancouver, BC [April 21, 2022] – Canada’s Digital Technology Supercluster is excited to be
February 17, 2022
Merger includes C$20 million investment to accelerate access to genomics-based testing for cancer treatment by combining Canexia Health’s advanced molecular cancer solutions with Imagia Cybernetics’ healthcare and AI expertise
January 10, 2022
Ensuring all cancer patients have access to next-generation cancer treatment selection and recurrence monitoring requires a fundamental shift in how and where care is delivered.
December 13, 2021
With a strategic investment from Canada’s Digital Technology Supercluster, a pilot project to bring ctDNA testing into the Canadian health system was launched in July 2020.
Every Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.